Moderna (MRNA) announced on Wednesday that it has completed its domestic end-to-end mRNA manufacturing network with the onshoring of drug product manufacturing to its Moderna Technology Center in Norwood, Massachusetts.
The COVID-19 vaccine maker said it has invested more than $140M for the construction, creating hundreds of highly skilled jobs in the biomanufacturing sector.
The biotech identified the development as a significant milestone in its efforts to boost its U.S. manufacturing network amid the Trump administration’s threats to impose tariffs on pharmaceuticals.
Major drugmakers such as Pfizer (PFE) and AstraZeneca (AZN) have reached pricing deals with the U.S. and pledged new domestic investments in exchange for a waiver on tariffs.
“As an American company committed to building and producing in America, we are proud to strengthen our domestic footprint while bringing meaningful new jobs to the community,” CEO Stéphane Bancel remarked.